Clinical Scorecard: FDA and CMS Initiatives to Support Gene Therapy Development and Access for Rare Diseases

At a Glance

Key Highlights

• FDA issued draft guidance on BLA submissions and postapproval management for individualized human genome-editing products.
• The Individualized Feature Space sets pre-established limits for patient-specific product variation within one BLA.
• For a new variant within those limits, the draft guidance describes submission using assays demonstrating adequate safety and activity, without further clinical trials; the pathway relies on trials supporting BLA approval and is supplemented by laboratory data.
• The draft guidance also addresses manufacturing, safety testing—including unintended genetic changes—and product naming and labeling.
• CMS plans to expand its voluntary Cell and Gene Therapy Access Model beyond sickle cell disease and invite manufacturers developing therapies for other conditions to apply.

Guideline-Based Recommendations

Diagnosis

Management

• The draft guidance describes BLA structure and postapproval management for individualized genome-editing products.
• The guidance describes adding variants within the specified IFS limits through a streamlined review pathway, relying on clinical trials supporting the original BLA and laboratory (in vitro) data concerning the new variant.
• CMS plans to issue a Request for Applications inviting manufacturers developing therapies for other conditions to apply to the expanded, voluntary Cell and Gene Therapy Access Model.

Monitoring & Follow-up

• The draft guidance addresses safety testing, including assessment of the risk of unintended genetic changes.
• For a new patient-specific variant within the IFS limits, the draft guidance describes assays demonstrating adequate safety and activity.

Risks

• The draft guidance identifies unintended genetic changes as a safety-testing consideration.
• The source does not provide patient-level adverse-event rates or quantify treatment risks.

Patient & Prescribing Data

People with rare genetic diseases whose mutations may vary between individuals, including patients with ultra-rare conditions; CMS's planned access-model expansion concerns state Medicaid programs and beneficiaries.

Individualized genome-editing products are designed to target each patient's genetic variant. The draft guidance describes a pathway for adding variants within the IFS limits without further clinical trials, relying on trials supporting BLA approval and supplemented by laboratory (in vitro) data on the new variant. No dosing or prescribing regimen is provided.

Clinical Best Practices

• The FDA draft guidance describes BLA submissions and postapproval management for individualized genome-editing products.
• The guidance describes defining an Individualized Feature Space to establish limits for patient-specific product variation within a BLA.
• The guidance addresses manufacturing, safety testing, product naming, and labeling.
• FDA invites public comments on the draft guidance through regulations.gov to docket FDA-2026-D-11783 within 30 days after Federal Register publication.

Related Resources & Content

• FDA draft guidance: Individualized Human Genome Editing Products: Considerations for BLA Submission and Postapproval Management
• FDA webinar: Individualized Human Genome Editing Products: Considerations for BLA and Postapproval Management